英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
---|---|---|---|---|---|---|
Sildenafil citrate
|
171599-83-0 |
枸橼酸西地那非
|
枸橼酸西地那非(伟哥、万艾可);枸橼酸西地那非 1KG;西地那非&远成;昔多芬杂质;1-[[3-(6,7-二氢-1-甲基-7-氧-3-丙基-1H-吡唑并-[4,3-d]嘧啶-5-基)-4-乙氧苯基]璜酰基]-5-甲基哌嗪柠檬酸盐;伟哥;西地那非枸橼酸;西地那非柠檬酸盐;万艾可
|
C22H30N6O4S.C6H8O7 |
666.69992 | 200-659-6 |
SGC707
|
1687736-54-4 |
N-6-异喹啉基-N'-[2-氧代-2-(1-吡咯烷基)乙基]脲
|
CS-2192;SGC 707;SGC707;N-6-异喹啉基-N'-[2-氧代-2-(1-吡咯烷基)乙基]脲;1-(异喹啉-6-基)-3-(2-氧代-2-(吡咯烷-1-基)乙基)脲
|
C16H18N4O2 |
298.33972 | |
1H-INDOLE-5-CARBOXAMIDE,
|
1670-87-7 |
1H-吲哚-5-甲酰胺
|
1H-吲哚-5-甲酰胺;5-(氨基羰基)-1H-吲哚;5-氨基甲酰吲哚;5-羧酰氨基吲哚;吲哚-5-甲酰胺
|
C9H8N2O |
160.17262 | |
Dinaciclib (SCH 727965)
|
779353-01-4 |
(2S)-1-[3-乙基-7-[[(1-氧代-3-吡啶基)甲基]氨基]吡唑并[1,5-A]嘧啶-5-基]-2-哌啶乙醇
|
DINACICLIB (SCH727965),≥98%;SCH 727965;SCH727965;SCH-727965;PS-095760;CS-213;DINACICLIB (SCH727965);SCH 727965;(2S)-1-[3-乙基-7-[[(1-氧代-3-吡啶基)甲基]氨基]吡唑并[1,5-A]嘧啶-5-基]-2-哌啶乙醇 100MG;(2S)-1-[3-乙基-7-[[(1-氧代-3-吡啶基)甲基]氨基]吡唑并[1,5-A]嘧啶-5-基]-2-哌啶乙醇;DINACICLIB(SCH-727965,PS-095760);SCH 727965DINACICLIB
|
C21H28N6O2 |
396.48602 | 214-589-6 |
SC 79
|
305834-79-1 |
2-氨基-6-氯-ALPHA-氰基-3-(乙氧羰基)-4H-1-苯并吡喃-4-乙酸乙酯
|
2-氨基-6-氯-ALPHA-氰基-3-(乙氧羰基)-4H-1-苯并吡喃-4-乙酸乙酯;CS-2177;SC79;SC 79;AKT ACTIVATOR II;SC79;SC 79;2-氨基-6-氯-ALPHA-氰基-3-(乙氧羰基)-4H-1-苯并吡喃-4-乙酸乙酯
|
C17H17ClN2O5 |
364.78028 | |
SC-26196
|
218136-59-5 |
ALPHA,ALPHA-二苯基-4-[(3-吡啶亚甲基)氨基]-1-吡嗪戊腈
|
SC 26196 - PF 06341724;SC 26196;α,α-Diphenyl-4-[(3-pyridinylmethylene)amino]-1-piperazinepentanenitrile;alpha,alpha-Diphenyl-4-[(3-pyridinylmethylene)amino]-1-piperazinepentanenitrile;α,α-Diphenyl-4-[(3-pyridinylMethylene)aMino]-1-piperazine;2,2-diphenyl-5-{4-[(E)-(pyridin-3-ylMethylidene)aMino]piperazin-1-yl}pentanenitrile;PF-o6341724;(E)-2,2-diphenyl-5-(4-((pyridin-3-ylMethylene)aMino)piperazin-1-yl)pentanenitrile
|
C27H29N5 |
423.55266 | |
SC 236-SC 58236
|
170569-86-5 |
4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
|
4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
|
C16H11ClF3N3O2S |
401.79 | |
SB939
|
929016-96-6 |
(2E)-3-[2-丁基-1-[2-(二乙基氨基)乙基]-1H-苯并咪唑-5-基]-N-羟基丙烯酰胺
|
PRACINOSTAT (SB939)>98%;CS-60;(2E)-3-[2-丁基-1-[2-(二乙基氨基)乙基]-1H-苯并咪唑-5-基]-N-羟基丙烯酰胺;(E)-3-(2-BUTYL-1-(2-(DIETHYLAMINO)ETHYL)-1H-BENZO[D]IMIDAZOL-5-YL)-N-HYDROXYACRYLAMIDE;(2E)-3-[2-丁基-1-[2-(二乙基氨基)乙基]-1H-苯并咪唑-5-基]-N-羟基丙烯酰胺 (SB 939);PRACINOSTAT (SB939);SB939;SB-939;SB939;SB-939;SB 939
|
C20H30N4O2 |
358.4778 | |
5-[2-[4-[2-(Dimethylamino)ethoxy]phenyl]-5-(4-pyridinyl)-1H-imidazol-4-yl]-2,3-dihydro-1H-inden-1-one oxime
|
405554-55-4 |
5-[2-[4-[2-(二甲基氨基)乙氧基]苯基]-5-(4-吡啶基)-1H-咪唑-4-基]-2,3-二氢-1-茚酮肟
|
5-[2-[4-[2-(二甲基氨基)乙氧基]苯基]-5-(4-吡啶基)-1H-咪唑-4-基]-2,3-二氢-1-茚酮肟;SB590885;SB-590885
|
C27H27N5O2 |
453.54 | |
SB 203580
|
152121-47-6 |
4-(4-氟苯基)-2-(4-甲基亚磺酰基苯基)-5-(4-吡啶基)-1H-咪唑
|
RWJ 64809;PB 203580;SB203580;SB-203580;SB203580;SB 203580;4-(4-氟苯基)-2-(4-甲基亚磺酰基苯基)-5-(4-吡啶基)-1H-咪唑;RWJ 64809;PB 203580;4-[5-(4-氟苯基)-2-[4-(甲基磺酰基)苯基]-1H-咪唑-4-基]-吡啶;SB-203580抑制剂;4-(4-(4-氟苯基)-2-(4-(甲基苯亚磺酰基)-苯基)-1H-咪唑基-5-基)吡啶
|
C21H16FN3OS |
377.43 | |
SB 202190
|
152121-30-7 |
4-(4-氟苯基)-2-(4-羟基苯基)-5-(4-吡啶基)-1H-咪唑
|
4-(4-氟苯基)-2-(4-羟基苯基)-5-(4-吡啶基)-1H-咪唑;4-[4-(4-氟苯基)-5-(4-吡啶基)-1H-咪唑-2-基]苯酚;4-(4-氟苯基)-2-(4-羟基苯基)-5-(4-吡啶基)-1H-咪唑 25MG;SB-202190;SB 202190
|
C20H14FN3O |
331.34 | |
RS-1
|
312756-74-4 |
4-溴-N-(4-溴苯基)-3-[[(苯基甲基)氨基]磺酰基]苯甲酰胺
|
大鼠皮肤成纤维样细胞;4-溴-N-(4-溴苯基)-3-[[(苯基甲基)氨基]磺酰基]苯甲酰胺
|
C20H16Br2N2O3S |
524.22564 | |
(4S)-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]PYRROLIDIN-2-ONE
|
85416-73-5 |
S- (+)-Rolipram
|
(+)-ROLIPRAM;(S)-ROLIPRAM;(S)-4-[3-(环戊基氧基)-4-甲氧基苯基]-2-吡咯烷酮;S-(+)-咯利普兰
|
C16H21NO3 |
275.34 | |
(4S)-4-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]PYRROLIDIN-2-ONE
|
85416-75-7 |
(4R)-4-[3-(环戊氧基)-4-甲氧基苯基]吡咯-2-酮
|
(R)-ROLIPRAM;(-)-ROLIPRAM;CS-1181;(4R)-4-[3-(环戊氧基)-4-甲氧基苯基]吡咯-2-酮;(R)-(-)-咯利普兰
|
C16H21NO3 |
275.34 | |
Roflumilast
|
162401-32-3 |
罗氟司特
|
罗氟司特(标准品);罗氟斯特;3-(环丙基甲氧基)-N-(3,5-二氯-4-吡啶基)-4-(二氟甲氧基)苯甲酰胺;罗氟司特;ROFLUMILAST;3-(环丙甲氧基)-N-(3,5-二氯-4-吡啶基)-4-(二氟甲氧基)苯甲酰胺;3-(环丙基甲氧基)-N-(3,5-二氯吡啶-4-基)-4-(二氟甲氧基)苯甲酰胺;罗氟司特;3-(环丙甲氧基)-N-(3,5-二氯-4-吡啶基)-5-(二氟甲氧基)苯甲酰胺
|
C17H14Cl2F2N2O3 |
403.207466 | 685-382-2 |
RO4929097
|
847925-91-1 |
N1-[(7S)-6,7-二氢-6-氧代-5H-二苯并[B,D]氮杂卓-7-基]-2,2-二甲基-N3-(2,2,3,3,3-五氟丙基)丙二酰胺
|
N1-[(7S)-6,7-二氢-6-氧代-5H-二苯并[B,D]氮杂卓-7-基]-2,2-二甲基-N3-(2,2,3,3-五氟丙基)丙二酰胺;RO-4929097;RO 4929097;CS-14;RO4929097;RO-4929097;RO 4929097;RO4929097 (RG-4733);RO 4929097,一种Γ SECRETASE抑制剂
|
C22H20F5N3O3 |
469.42 | |
RI-1
|
415713-60-9 |
3-氯-1-(3,4-二氯苯基)-4-(4-吗啉基)-1H-吡咯-2,5-二酮
|
3-氯-1-(3,4-二氯苯基)-4-(4-吗啉基)-1H-吡咯-2,5-二酮;13-氯-1-(3;RI1;RI-1;4-二氯苯基)-4-(4-吗啉基)-1H-吡咯-2
|
C14H11Cl3N2O3 |
361.60774 | |
Regorafenib
|
755037-03-7 |
瑞格非尼
|
五氟丙酸钠盐;REGORAFENIB;BAY 73-4506;SORAFENIB;BAY-73-4506;BAY 73 4506;格非尼相关杂质;雷戈非尼;瑞戈非尼无水物;4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-N-甲基吡啶-2-甲酰胺;REGORAFENIB BAY 73-4507 BAYER HEALTHCARE (SEE ALSO COLORECTAL,LUNG,STOMACH)PHASE II(REGORAFENIB)PHARM
|
C21H15N4O3F4Cl.HCl |
519.27634 | |
Sirolimus
|
53123-88-9 |
雷帕霉素
|
雷帕霉素;雷帕霉素-D3 (雷帕霉素-D3);雷帕霉素(98%细胞干扰;99%器官移植);雷帕霉素D3;雷帕霉素,来源于吸水链霉菌
|
C51H79NO13 |
914.18 | |
R547
|
741713-40-6 |
[4-氨基-2-[(1-甲磺酰基哌啶-4-基)氨基]嘧啶-5-基](2,3-二氟-6-甲氧基苯基)甲酮
|
CS-238;[4-氨基-2-[(1-甲磺酰基哌啶-4-基)氨基]嘧啶-5-基](2,3-二氟-6-甲氧基苯基)甲酮
|
C18H21F2N5O4S |
441.45 |